How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

356 results for

autism and SSRIs

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). (Abstract)

Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Autism spectrum disorders (ASD) are characterised by abnormalities in social interaction and communication skills, as well as stereotypic behaviours and restricted activities and interests. Selective serotonin reuptake inhibitors (SSRIs) are prescribed for the treatment of conditions often comorbid with ASD such as depression, anxiety and obsessive-compulsive behaviours.To determine if treatment with an SSRI:1 (...) and the International Clinical Trials Registry Platform (ICTRP). This was supplemented by searching reference lists and contacting known experts in the field.Randomised controlled trials (RCTs) of any dose of oral SSRI compared with placebo, in people with ASD.Two authors independently selected studies for inclusion, extracted data and appraised each study's risk of bias.Nine RCTs with a total of 320 participants were included. Four SSRIs were evaluated: fluoxetine (three studies), fluvoxamine (two studies

2013 Cochrane

2. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for attention deficit hyperactivity disorder and autistic spectrum disorder: a systematic review, meta-analysis, and network meta-analys

Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for attention deficit hyperactivity disorder and autistic spectrum disorder: a systematic review, meta-analysis, and network meta-analys Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied (...) : Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title

2019 PROSPERO

3. Selective Serotonin Reuptake Inhibitor Monotherapy for Anxiety Disorders in Children and Adolescents with Autism Spectrum Disorder: A Chart Review. (Abstract)

Selective Serotonin Reuptake Inhibitor Monotherapy for Anxiety Disorders in Children and Adolescents with Autism Spectrum Disorder: A Chart Review. Objective: Anxiety disorders are one of the most commonly co-occurring psychiatric diagnoses in youth with autism spectrum disorder (ASD), with a frequency ranging from 22% to 84%. Methods: We conducted a chart review of 29 children and adolescents with ASD who had been treated with selective serotonin reuptake inhibitor (SSRI) monotherapy (...) patients discontinued treatment owing to AEs. Other reported AEs not leading to discontinuation included vivid dreaming, increased emotional lability, and irritability. Responders included a number of patients who had failed previous SSRI trials. Conclusions: This study suggests that SSRI treatment should be considered for individuals with ASD and anxiety disorders, even if prior SSRI trials have been unsuccessful.

2019 Journal of Child and Adolescent Psychopharmacology

4. Efficacy and safety of Selective Serotonin Reuptake Inhibitors in children with Autism Spectrum Disorders: a systematic review and meta-analysis.

Efficacy and safety of Selective Serotonin Reuptake Inhibitors in children with Autism Spectrum Disorders: a systematic review and meta-analysis. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) : Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review

2020 PROSPERO

5. Activation in Children and Adolescents Treated With Selective Serotonin Reuptake Inhibitors: A Weighty Reason? (Abstract)

Activation in Children and Adolescents Treated With Selective Serotonin Reuptake Inhibitors: A Weighty Reason? Activation is a behavioral adverse event related to the use of psychotropic medication. Its high incidence in pediatrics and in childhood-onset neuropsychiatric disorders suggests it may be linked to neurodevelopment. However, previous studies have scarcely examined the role that factors relevant to developmental pharmacokinetics, such as body weight, may play in the onset (...) of activation in children and adolescents.We conducted a retrospective analysis of hospitalized patients to identify the risk factors for activation in children and adolescents treated with selective serotonin reuptake inhibitors. Our focus was on factors related to development, including body weight, to explore the relationship between activation and neurodevelopmental processes.Among the 139 participants (mean age, 14 ± 2.3 years), activation appeared in 29 (20.9%). Age 12 years or younger and comorbid

2018 Journal of Clinical Psychopharmacology

6. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). (Abstract)

Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Autism spectrum disorders (ASD) are characterised by abnormalities in social interaction and communication skills, as well as stereotypic behaviours and restricted activities and interests. Selective serotonin reuptake inhibitors (SSRIs) are prescribed for the treatment of co-morbidity associated with ASD such as depression, anxiety and obsessive-compulsive behaviours.To determine if treatment with an SSRI: 1 (...) (December 2009) and ERIC (December 2009), without language restrictions.Randomised controlled trials (RCTs) of any dose of oral SSRI compared with placebo, in participants with autism spectrum disorders. Trials must have included at least one standardised outcome measure.Two authors independently selected and appraised studies for inclusion and risk of bias. All data were continuous. Meta-analysis, where possible, used a random-effects model.Seven RCTs with a total of 271 participants were included

2010 Cochrane

7. Risk of autism spectrum disorder in offspring following paternal use of selective serotonin reuptake inhibitors before conception: a population-based cohort study. Full Text available with Trip Pro

Risk of autism spectrum disorder in offspring following paternal use of selective serotonin reuptake inhibitors before conception: a population-based cohort study. The present study aimed to examine the association between paternal selective serotonin reuptake inhibitor (SSRI) use before conception and the risk of autism spectrum disorder (ASD) in offspring.A population-based cohort study.We conducted a cohort study of 669 922 children born from 1998 to 2008, with follow-up throughout 2013 (...) . Based on Danish national registers, we linked information on paternal use of SSRIs, ASD diagnosed in children and a range of potential confounders. The children whose fathers used SSRIs during the last 3 months prior to conception were identified as the exposed. Cox regression model was used to estimate the HR for ASD in children.Compared with unexposed children, the exposed had a 1.62-fold higher risk of ASD (95% CI 1.33 to 1.96) and the risk attenuated after adjusting for potential confounders

2017 BMJ open

8. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. Full Text available with Trip Pro

Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. Studies have raised concern about an association between the use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy and an increased risk of autism spectrum disorders in the offspring.We conducted a cohort study of all singleton live births in Denmark from 1996 through 2005 (626,875 births), with follow-up through 2009. Using Danish population registries, we linked information on maternal use (...) of SSRIs before and during pregnancy, autism spectrum disorders diagnosed in the offspring, and a range of potential confounders. We used a survival analysis of the time to diagnosis in the offspring with Poisson regression to estimate rate ratios of autism spectrum disorders according to maternal use of SSRIs.During 5,057,282 person-years of follow-up, we identified 3892 cases of autism spectrum disorder (incidence rate, 77.0 per 100,000 person-years). A total of 52 cases during 42,400 person-years

2013 NEJM

9. Gestational Exposure to Selective Serotonin Reuptake Inhibitors and Offspring Psychiatric Disorders: A National Register-Based Study. Full Text available with Trip Pro

Gestational Exposure to Selective Serotonin Reuptake Inhibitors and Offspring Psychiatric Disorders: A National Register-Based Study. To investigate the impact of gestational exposure to selective serotonin reuptake inhibitors (SSRIs) on offspring neurodevelopment.This is a cohort study using national register data in Finland between the years 1996 and 2010. Pregnant women and their offspring were categorized into 4 groups: SSRI exposed (n = 15,729); exposed to psychiatric disorder (...) , no antidepressants (n = 9,651); exposed to SSRIs only before pregnancy (n = 7,980); and unexposed to antidepressants and psychiatric disorders (n = 31,394). We investigated the cumulative incidence of offspring diagnoses of depression, anxiety, autism spectrum disorder (ASD), and attention-deficit/hyperactivity disorder (ADHD) for the 4 groups from birth to 14 years, adjusting for confounders.The cumulative incidence of depression among offspring exposed prenatally to SSRIs was 8.2% (95% CI = 3.1-13.3%) by age

2016 Journal of the American Academy of Child and Adolescent Psychiatry

10. Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2013 Clinical Trials

11. Selective serotonin reuptake inhibitors for the treatment of autism

: HAYES, Inc.. 2009 Authors' objectives Serotonergic abnormalities may contribute to the underlying etiology of autism. Therefore, selective serotonin reuptake inhibitors (SSRIs) are increasingly being prescribed as an off-label treatment for children and adults with autism. The goal of SSRI treatment is to minimize the severity of core behavioral deficits and associated behaviors, maximize functionality, and improve quality of life for autistic individuals and their families. Project page URL (...) Selective serotonin reuptake inhibitors for the treatment of autism Selective serotonin reuptake inhibitors for the treatment of autism Selective serotonin reuptake inhibitors for the treatment of autism Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from . Citation Selective serotonin reuptake inhibitors for the treatment of autism . Lansdale

2009 Health Technology Assessment (HTA) Database.

12. Selective serotonin reuptake inhibitor-related extrapyramidal symptoms in autistic children: a case series. (Abstract)

Selective serotonin reuptake inhibitor-related extrapyramidal symptoms in autistic children: a case series. Abnormal movements occur rarely with selective serotonin reuptake inhibitors (SSRIs). This report describes four consecutive autistic children who developed extrapyramidal side effects (EPS) following SSRI exposure. Videotapes, physician notes, and parental interviews were used retrospectively to rate symptoms on the Extrapyramidal Symptom Rating Scale. Findings suggest that EPS (...) is a potential complication of SSRI treatment in autistic children.

1 Journal of Child and Adolescent Psychopharmacology

13. A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive-Compulsive Disorder

A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive-Compulsive Disorder A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved (...) Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read

2012 Clinical Trials

14. Examining the Reversibility of Long-Term Behavioral Disruptions in Progeny of Maternal SSRI Exposure Full Text available with Trip Pro

Examining the Reversibility of Long-Term Behavioral Disruptions in Progeny of Maternal SSRI Exposure Serotonergic dysregulation is implicated in numerous psychiatric disorders. Serotonin plays widespread trophic roles during neurodevelopment; thus perturbations to this system during development may increase risk for neurodevelopmental disorders. Epidemiological studies have examined association between selective serotonin reuptake inhibitor (SSRI) treatment during pregnancy and increased autism (...) spectrum disorder (ASD) risk in offspring. It is unclear from these studies whether ASD susceptibility is purely related to maternal psychiatric diagnosis, or if treatment poses additional risk. We sought to determine whether maternal SSRI treatment alone or in combination with genetically vulnerable background was sufficient to induce offspring behavior disruptions relevant to ASD. We exposed C57BL/6J or Celf6+/- mouse dams to fluoxetine (FLX) during different periods of gestation and lactation

2018 eNeuro

15. Perinatal SSRI Exposure Permanently Alters Cerebral Serotonin Receptor mRNA in Mice But Does Not Impact Adult Behaviors Full Text available with Trip Pro

Perinatal SSRI Exposure Permanently Alters Cerebral Serotonin Receptor mRNA in Mice But Does Not Impact Adult Behaviors Associations have been made between maternal selective serotonin reuptake inhibitor (SSRI) use during pregnancy and altered behavior in offspring, including an increased risk of autism. Given the important role serotonin plays in behavior, we hypothesized SSRI exposure in the perinatal period would alter central serotonin receptor expression and program adult behaviors (...) in mice.Female mice were injected with sertraline or saline throughout pregnancy. Offspring continued to receive injections on postnatal days 1-14, a time period in mice similar to the third trimester in human pregnancy. Adult offspring underwent behavioral testing, and serotonin receptor mRNA levels were quantified.Compared to controls, SSRI exposed mice did not have a reduction in social interactions, spatial learning, or exploratory behavior. As adults, sertraline exposed mice had significantly increased

2017 The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians

16. SSRIs

SSRIs USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN PREGNANCY 0344 892 0909 USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN PREGNANCY (Date of issue: January 2017 , Version: 2.2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Six selective serotonin reuptake inhibitors (SSRIs) are licensed in the UK (...) . However, study sample sizes are often small and many assessments were undertaken in children under one year of age. A number of studies have suggested an association with autism spectrum disorder (ASD) but as some of these studies have also suggested associations may exist between ASD and the underlying maternal condition, the findings may be confounded. Offspring neurodevelopment following maternal use of SSRIs in pregnancy requires further investigation before further conclusions can be provided

2014 UK Teratology Information Service

17. Selective serotonin reuptake inhibitor Full Text available with Trip Pro

and risk of autism". The New England Journal of Medicine . 369 (25): 2406–15. : . . ^ Malm H, Brown AS, Gissler M, Gyllenberg D, Hinkka-Yli-Salomäki S, McKeague IW, Weissman M, Wickramaratne P, Artama M, Gingrich JA, Sourander A, et al. (May 2016). . Journal of the American Academy of Child and Adolescent Psychiatry . 55 (5): 359–66. : . . . ^ Isbister GK, Bowe SJ, Dawson A, Whyte IM (2004). "Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose". Journal of Toxicology (...) Selective serotonin reuptake inhibitor Selective serotonin reuptake inhibitor - Wikipedia Selective serotonin reuptake inhibitor From Wikipedia, the free encyclopedia "SSRI" redirects here. For other uses, see . drugs for depression Selective serotonin reuptake inhibitor , the neurotransmitter that is involved in the mechanism of action of SSRIs. Class identifiers Serotonin-specific reuptake inhibitors, serotonergic antidepressants Use , Clinical data External links Selective serotonin reuptake

2012 Wikipedia

18. Prenatal SSRI exposure and autism risk: a dilemma for mums-to-be with depression

-term consequences of antidepressants in pregnancy are unclear, and difficult to study. Treating depression in pregnancy is important, but prescribing in pregnancy is tricky and there is limited evidence to guide clinical decision making. The British Journal of Psychiatry has published three papers about prescribing selective serotonin re-uptake inhibitor (SSRI) antidepressants in pregnancy; an original research paper 4 and two invited commentaries 5, 6 . This blog is principally about the original (...) measures taken from the mother and father. Although these measures are useful screens in large populations, the symptoms of autism or autistic traits are not the same as clinically relevant autism. There were fewer children in the ‘exposed to SSRI group’ with wider confidence intervals (CIs). In their invited commentary, Petersen et al 6 ,made an interpretation in relation to this. They noted that the CIs of the ‘exposed to depression’ group lie within that of the ‘exposed to SSRI’ group for pervasive

2014 The Mental Elf

19. Prenatal SSRI exposure and autism risk: a dilemma for mums-to-be with depression

-term consequences of antidepressants in pregnancy are unclear, and difficult to study. Treating depression in pregnancy is important, but prescribing in pregnancy is tricky and there is limited evidence to guide clinical decision making. The British Journal of Psychiatry has published three papers about prescribing selective serotonin re-uptake inhibitor (SSRI) antidepressants in pregnancy; an original research paper 4 and two invited commentaries 5, 6 . This blog is principally about the original (...) measures taken from the mother and father. Although these measures are useful screens in large populations, the symptoms of autism or autistic traits are not the same as clinically relevant autism. There were fewer children in the ‘exposed to SSRI group’ with wider confidence intervals (CIs). In their invited commentary, Petersen et al 6 ,made an interpretation in relation to this. They noted that the CIs of the ‘exposed to depression’ group lie within that of the ‘exposed to SSRI’ group for pervasive

2014 The Mental Elf

20. Prenatal SSRI Use and Offspring With Autism Spectrum Disorder or Developmental Delay. Full Text available with Trip Pro

Prenatal SSRI Use and Offspring With Autism Spectrum Disorder or Developmental Delay. To examine associations between prenatal use of selective serotonin reuptake inhibitors (SSRIs) and the odds of autism spectrum disorders (ASDs) and other developmental delays (DDs).A total of 966 mother-child pairs were evaluated (492 ASD, 154 DD, 320 typical development [TD]) from the Childhood Autism Risks from Genetics and the Environment (CHARGE) Study, a population-based case-control study. Standardized (...) measures confirmed developmental status. Interviews with biological mothers ascertained prenatal SSRI use, maternal mental health history, and sociodemographic information.Overall, prevalence of prenatal SSRI exposure was lowest in TD children (3.4%) but did not differ significantly from ASD (5.9%) or DD (5.2%) children. Among boys, prenatal SSRI exposure was nearly 3 times as likely in children with ASD relative to TD (adjusted odds ratio [OR]: 2.91; 95% confidence interval [CI]: 1.07-7.93

2014 Pediatrics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>